LEAP2 Reduces Ad Libitum Food Intake and Attenuates Postprandial Glucose Excursions in Men With Obesity - PubMed
6 hours ago
- #glucose
- #obesity
- #LEAP2
- LEAP2 is a peptide that acts as a ghrelin receptor antagonist.
- In a study with 20 men with obesity, LEAP2 infusion reduced ad libitum food intake by approximately 12%.
- LEAP2 infusion also lowered postprandial plasma glucose levels.
- These effects support LEAP2's potential therapeutic use in obesity and metabolic conditions.